MedWatch

EMA starts rolling review for Eli Lilly's Covid-19 treatment

Two new antibodies for Covid-19 have been placed under rolling review by the EMA. This will ensure faster approval in case the drug reaches the point of submitting an application.

Photo: MIKE SEGAR/REUTERS / X90033

The European Medicines Agency (EMA) has started reviewing the preliminary data on two Eli Lilly treatments for Covid-19, writes the Danish Medicines Agency in a press announcement.

This will be in the form of a rolling review of the antibody bamlanivimab and a bamlanivimab-etesevimab combination.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs